Datopotamab Deruxtecan (Dato-DXd) + Durvalumab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Oct 27, 2025 → Feb 1, 2030
NCT ID
NCT06954480About Datopotamab Deruxtecan (Dato-DXd) + Durvalumab
Datopotamab Deruxtecan (Dato-DXd) + Durvalumab is a phase 2 stage product being developed by AstraZeneca for Triple Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06954480. Target conditions include Triple Negative Breast Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06954480 | Phase 2 | Recruiting |
Competing Products
20 competing products in Triple Negative Breast Cancer